Build Your Comparison

Side-by-side financial analysis
ACOG logo
ACOG
SAVA logo
SAVA
AVXL logo
AVXL
PRAX logo
PRAX
JPM logo
JPM
Try popular comparisons:

Stock Comparison

ACOG vs SAVA vs AVXL vs PRAX vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ACOG
Alpha Cognition Inc. Common Stock

Financial - Conglomerates

Financial ServicesNASDAQ • CA
Market Cap$98M
5Y Perf.-4.8%
SAVA
Cassava Sciences, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$64M
5Y Perf.-40.6%
AVXL
Anavex Life Sciences Corp.

Biotechnology

HealthcareNASDAQ • US
Market Cap$232M
5Y Perf.-73.6%
PRAX
Praxis Precision Medicines, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$7.70B
5Y Perf.+232.5%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$896.00B
5Y Perf.+28.4%

ACOG vs SAVA vs AVXL vs PRAX vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ACOG logoACOG
SAVA logoSAVA
AVXL logoAVXL
PRAX logoPRAX
JPM logoJPM
IndustryFinancial - ConglomeratesBiotechnologyBiotechnologyBiotechnologyBanks - Diversified
Market Cap$98M$64M$232M$7.70B$896.00B
Revenue (TTM)$11M$0.00$0.00$280.33B
Net Income (TTM)$-25M$-106M$-40M$-327M$57.05B
Gross Margin86.4%60.0%
Operating Margin-250.1%25.9%
Forward P/E14.4x
Total Debt$0.00$0.00$0.00$110K$942.38B
Cash & Equiv.$66M$129M$103M$357M$343.34B

ACOG vs SAVA vs AVXL vs PRAX vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ACOG
SAVA
AVXL
PRAX
JPM
StockNov 24Jun 26Return
Alpha Cognition Inc… (ACOG)10095.2-4.8%
Cassava Sciences, I… (SAVA)10059.4-40.6%
Anavex Life Science… (AVXL)10026.4-73.6%
Praxis Precision Me… (PRAX)100332.5+232.5%
JPMorgan Chase & Co. (JPM)100128.4+28.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: ACOG vs SAVA vs AVXL vs PRAX vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: JPM leads in 5 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and profitability and margin quality. Alpha Cognition Inc. Common Stock is the stronger pick specifically for valuation and capital efficiency. PRAX also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇JPM emerged as the overall leader. Track its performance:
ACOG
Alpha Cognition Inc. Common Stock
The Banking Pick

ACOG is the #2 pick in this set and the best alternative if bank quality is your priority.

  • NIM 2.4% vs JPM's 2.2%
  • Better valuation composite
Best for: bank quality
SAVA
Cassava Sciences, Inc.
The Healthcare Pick

SAVA lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
AVXL
Anavex Life Sciences Corp.
The Healthcare Pick

Among these 5 stocks, AVXL doesn't own a clear edge in any measured category.

Best for: healthcare exposure
PRAX
Praxis Precision Medicines, Inc.
The Defensive Pick

PRAX ranks third and is worth considering specifically for sleep-well-at-night.

  • Lower volatility, beta 1.55, Low D/E 0.0%, current ratio 10.22x
  • +491.9% vs AVXL's -69.6%
Best for: sleep-well-at-night
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 15 yrs, beta 0.94, yield 1.9%
  • Rev growth 3.3%, EPS growth 1.5%
  • 465.8% 10Y total return vs ACOG's -11.3%
  • Beta 0.94, yield 1.9%, current ratio 0.52x
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthJPM logoJPM3.3% NII/revenue growth vs SAVA's -5.4%
ValueACOG logoACOGBetter valuation composite
Quality / MarginsJPM logoJPM20.4% margin vs ACOG's -232.2%
Stability / SafetyJPM logoJPMBeta 0.94 vs SAVA's 1.92
DividendsJPM logoJPM1.9% yield; 15-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)PRAX logoPRAX+491.9% vs AVXL's -69.6%
Efficiency (ROA)JPM logoJPM1.3% ROA vs SAVA's -75.3%, ROIC 4.5% vs -6.3%

ACOG vs SAVA vs AVXL vs PRAX vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ACOGAlpha Cognition Inc. Common Stock
FY 2025
Service
100.0%$433,221
SAVACassava Sciences, Inc.

Segment breakdown not available.

AVXLAnavex Life Sciences Corp.

Segment breakdown not available.

PRAXPraxis Precision Medicines, Inc.
FY 2024
License
76.8%$9M
Upfront Payment
23.2%$3M
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000

ACOG vs SAVA vs AVXL vs PRAX vs JPM — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJPMLAGGINGPRAX

Income & Cash Flow (Last 12 Months)

JPM leads this category, winning 3 of 5 comparable metrics.

JPM and PRAX operate at a comparable scale, with $280.3B and $0 in trailing revenue. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to ACOG's -2.3%.

MetricACOG logoACOGAlpha Cognition I…SAVA logoSAVACassava Sciences,…AVXL logoAVXLAnavex Life Scien…PRAX logoPRAXPraxis Precision …JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$11M$0$0$280.3B
EBITDAEarnings before interest/tax-$27M-$110M-$39M-$357M$81.4B
Net IncomeAfter-tax profit-$25M-$106M-$40M-$327M$57.0B
Free Cash FlowCash after capex-$30M-$84M-$34M-$283M$100.9B
Gross MarginGross profit ÷ Revenue+86.4%+60.0%
Operating MarginEBIT ÷ Revenue-2.5%+25.9%
Net MarginNet income ÷ Revenue-2.3%+20.4%
FCF MarginFCF ÷ Revenue-2.8%+36.0%
Rev. Growth (YoY)Latest quarter vs prior year
EPS Growth (YoY)Latest quarter vs prior year-146.2%+62.1%+54.4%+2.7%+16.0%
JPM leads this category, winning 3 of 5 comparable metrics.

Valuation Metrics

Evenly matched — SAVA and PRAX and JPM each lead in 1 of 3 comparable metrics.
MetricACOG logoACOGAlpha Cognition I…SAVA logoSAVACassava Sciences,…AVXL logoAVXLAnavex Life Scien…PRAX logoPRAXPraxis Precision …JPM logoJPMJPMorgan Chase & …
Market CapShares × price$98M$64M$232M$7.7B$896.0B
Enterprise ValueMkt cap + debt − cash$32M-$65M$129M$7.3B$1.50T
Trailing P/EPrice ÷ TTM EPS-5.38x-2.54x-4.63x-19.77x16.00x
Forward P/EPrice ÷ next-FY EPS est.14.40x
PEG RatioP/E ÷ EPS growth rate0.90x
EV / EBITDAEnterprise value multiple18.36x
Price / SalesMarket cap ÷ Revenue9.57x3.20x
Price / BookPrice ÷ Book value/share1.78x0.42x2.25x6.83x2.47x
Price / FCFMarket cap ÷ FCF8.88x
Evenly matched — SAVA and PRAX and JPM each lead in 1 of 3 comparable metrics.

Profitability & Efficiency

JPM leads this category, winning 5 of 8 comparable metrics.

JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-96 for SAVA. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), JPM scores 5/9 vs AVXL's 2/9, reflecting solid financial health.

MetricACOG logoACOGAlpha Cognition I…SAVA logoSAVACassava Sciences,…AVXL logoAVXLAnavex Life Scien…PRAX logoPRAXPraxis Precision …JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity-54.1%-95.8%-38.8%-43.0%+15.9%
ROA (TTM)Return on assets-41.8%-75.3%-35.0%-40.2%+1.3%
ROICReturn on invested capital-32.4%-6.3%-65.0%+4.5%
ROCEReturn on capital employed-38.4%-99.9%-47.8%-49.3%+8.9%
Piotroski ScoreFundamental quality 0–942235
Debt / EquityFinancial leverage0.00x2.60x
Net DebtTotal debt minus cash-$66M-$129M-$103M-$357M$599.0B
Cash & Equiv.Liquid assets$66M$129M$103M$357M$343.3B
Total DebtShort + long-term debt$0$0$0$110,000$942.4B
Interest CoverageEBIT ÷ Interest expense0.74x
JPM leads this category, winning 5 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — PRAX and JPM each lead in 3 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $1,191 for AVXL. Over the past 12 months, PRAX leads with a +491.9% total return vs AVXL's -69.6%. The 3-year compound annual growth rate (CAGR) favors PRAX at 164.8% vs AVXL's -33.9% — a key indicator of consistent wealth creation.

MetricACOG logoACOGAlpha Cognition I…SAVA logoSAVACassava Sciences,…AVXL logoAVXLAnavex Life Scien…PRAX logoPRAXPraxis Precision …JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date-3.1%-36.8%-32.1%-6.9%-0.5%
1-Year ReturnPast 12 months-34.4%-37.7%-69.6%+491.9%+21.8%
3-Year ReturnCumulative with dividends-11.3%-62.5%-71.1%+1757.4%+138.2%
5-Year ReturnCumulative with dividends-11.3%-87.8%-88.1%-14.2%+118.2%
10-Year ReturnCumulative with dividends-11.3%-38.0%-38.3%-36.1%+465.8%
CAGR (3Y)Annualised 3-year return-3.9%-27.9%-33.9%+164.8%+33.6%
Evenly matched — PRAX and JPM each lead in 3 of 6 comparable metrics.

Risk & Volatility

JPM leads this category, winning 2 of 2 comparable metrics.

JPM is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than SAVA's 1.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 95.1% from its 52-week high vs AVXL's 17.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricACOG logoACOGAlpha Cognition I…SAVA logoSAVACassava Sciences,…AVXL logoAVXLAnavex Life Scien…PRAX logoPRAXPraxis Precision …JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 5001.29x1.92x1.77x1.55x0.94x
52-Week HighHighest price in past year$11.54$4.98$13.99$366.52$337.25
52-Week LowLowest price in past year$4.50$1.27$2.41$37.19$262.71
% of 52W HighCurrent price vs 52-week peak+54.6%+26.5%+17.9%+72.7%+95.1%
RSI (14)Momentum oscillator 0–10050.942.736.831.959.1
Avg Volume (50D)Average daily shares traded42K134K1.0M396K7.0M
JPM leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

JPM leads this category, winning 1 of 1 comparable metric.

Analyst consensus: ACOG as "Buy", SAVA as "Buy", AVXL as "Buy", PRAX as "Buy", JPM as "Buy". Consensus price targets imply 340.0% upside for AVXL (target: $11) vs 5.9% for JPM (target: $340). JPM is the only dividend payer here at 1.86% yield — a key consideration for income-focused portfolios.

MetricACOG logoACOGAlpha Cognition I…SAVA logoSAVACassava Sciences,…AVXL logoAVXLAnavex Life Scien…PRAX logoPRAXPraxis Precision …JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$14.00$11.00$607.15$339.75
# AnalystsCovering analysts112131661
Dividend YieldAnnual dividend ÷ price+1.9%
Dividend StreakConsecutive years of raises0015
Dividend / ShareAnnual DPS$5.95
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%+3.9%
JPM leads this category, winning 1 of 1 comparable metric.
Key Takeaway

JPM leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.

Best OverallJPMorgan Chase & Co. (JPM)Leads 4 of 6 categories
Loading custom metrics...

ACOG vs SAVA vs AVXL vs PRAX vs JPM: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is ACOG or SAVA or AVXL or PRAX or JPM a better buy right now?

For growth investors, JPMorgan Chase & Co.

(JPM) is the stronger pick with 3. 3% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Alpha Cognition Inc. Common Stock (ACOG) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — ACOG or SAVA or AVXL or PRAX or JPM?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -88. 1% for Anavex Life Sciences Corp. (AVXL). Over 10 years, the gap is even starker: JPM returned +465. 8% versus AVXL's -38. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — ACOG or SAVA or AVXL or PRAX or JPM?

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 94β versus Cassava Sciences, Inc. 's 1. 92β — meaning SAVA is approximately 104% more volatile than JPM relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

04

Which is growing faster — ACOG or SAVA or AVXL or PRAX or JPM?

By revenue growth (latest reported year), JPMorgan Chase & Co.

(JPM) is pulling ahead at 3. 3% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc. grew EPS 77. 6% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — ACOG or SAVA or AVXL or PRAX or JPM?

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -202. 2% for Alpha Cognition Inc. Common Stock — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -221. 7% for ACOG. At the gross margin level — before operating expenses — ACOG leads at 81. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is ACOG or SAVA or AVXL or PRAX or JPM more undervalued right now?

Analyst consensus price targets imply the most upside for AVXL: 340.

0% to $11. 00.

07

Which pays a better dividend — ACOG or SAVA or AVXL or PRAX or JPM?

In this comparison, JPM (1.

9% yield) pays a dividend. ACOG, SAVA, AVXL, PRAX do not pay a meaningful dividend and should not be held primarily for income.

08

Is ACOG or SAVA or AVXL or PRAX or JPM better for a retirement portfolio?

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Cassava Sciences, Inc. (SAVA) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, SAVA: -38. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between ACOG and SAVA and AVXL and PRAX and JPM?

These companies operate in different sectors (ACOG (Financial Services) and SAVA (Healthcare) and AVXL (Healthcare) and PRAX (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ACOG is a small-cap quality compounder stock; SAVA is a small-cap quality compounder stock; AVXL is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while ACOG, SAVA, AVXL, PRAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.